Upsher-Smith launches new DMD support websites for Kymbee treatment
Sites offer guidance on starting therapy, access, and ongoing support
Written by |
Upsher-Smith Laboratories has launched two new websites to support people with Duchenne muscular dystrophy (DMD) who are taking its recently introduced corticosteroid therapy Kymbee (deflazacort).
One website is designed specifically for caregivers of children with DMD. It offers tips for talking with healthcare providers about treatment, along with a step-by-step guide on how to start Kymbee if it is prescribed.
The caregiver website also provides details about Upsher-Smith’s Promise of Support program, which connects families with a specialized team to help navigate issues such as insurance coverage and ensure timely delivery and continued access to treatment.
Websites offer support for both caregivers and healthcare providers
The other website is designed for healthcare providers. It offers resources to help make prescribing Kymbee as simple as possible and to ensure patients have uninterrupted access to treatment.
“Our goal is to make the treatment journey as seamless as possible for both families and healthcare providers,” Michelle Zachman, medical affairs director at Upsher-Smith, said in a company press release. “The new KYMBEE caregiver and healthcare professional websites were built with the Duchenne community in mind—offering information, easy navigation, and practical tools that help reduce barriers, support timely access, and ensure families and clinicians have resources they need every step of the way.”
DMD is a genetic disorder in which patients produce little to no dystrophin, a protein that is vital for maintaining muscle health. Without dystrophin, muscles become damaged over time, leading to symptoms such as muscle weakness and wasting.
Inflammation is thought to play a role in DMD muscle damage, and corticosteroids — medications that work to mimic the activity of cortisol, an anti-inflammatory hormone — have long been a mainstay of treatment. Corticosteroids have been shown to slow the decline of muscle function in DMD, helping patients retain motor function for longer.
Upsher-Smith launched Kymbee late last year as an oral tablet formulation of deflazacort, a corticosteroid medication. Kymbee is approved in the U.S. to treat DMD in patients ages 5 and older. Another formulation of the same corticosteroid has been approved in the U.S. since 2017 under the name Emflaza, which is marketed by PTC Therapeutics.
Leave a comment
Fill in the required fields to post. Your email address will not be published.